Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

• Status: Recruiting
• Trial end date: 2027-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tyra Biosciences, Inc

Criteria

Inclusion Criteria:

Phase 1 Part A

• Men and women 18 years of age or older.

• Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

• Any histologically confirmed advanced solid tumor with FGFR/FGF pathway alterations including FGFR gene mutations, fusions, and amplifications, as well as gene amplifications of FGFR ligands, who have exhausted or refused approved standard therapies.

• Evaluable disease according to RECIST v1.1.

Phase 1 Part B

• Men and women 18 years of age or older.

• Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

• Histologically confirmed locally advanced/metastatic intrahepatic cholangiocarcinoma with a previously identified FGFR2 gene mutation or rearrangement.

• Must have received a prior FGFR inhibitor. Participants may have received more than 1 prior FGFR inhibitor.

• Presence of an FGFR2 kinase domain mutation that confers resistance to previous/other FGFR inhibitors; resistance mutations should be identified by a US Food and Drug Administration authorized/approved companion diagnostic or a Clinical Laboratory Improvement Amendments (CLIA) validated local test performed in a certified laboratory.

• At least 1 measurable lesion by RECIST v1.1.

Exclusion Criteria:

• Discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity ≥Grade 3 or any Grade 4 toxicity according to CTCAE v5.0.

• Has a serum phosphorus level > upper limit of normal (ULN) during screening that remains >ULN despite medical management.

• Any ocular condition likely to increase the risk of eye toxicity.

• History of or current uncontrolled cardiovascular disease.

• Active, symptomatic, or untreated brain metastases.

• Gastrointestinal disorders that will affect oral administration or absorption of TYRA-200.

• Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.